Ryan Gentzler, MD, MS

Privileged to have been there for this out of the box lecture. So many great perspectives!

08.03.2025 05:05 — 👍 2    🔁 1    💬 1    📌 0

⭐️CRS and ICANS manageable with appropriate monitoring & interventions. Short time to resolution.

Full poster here:

23.02.2025 12:53 — 👍 2    🔁 0    💬 0    📌 0

Congratulations to our fellow, Sean Dougherty, for his work presented at @iaslc.bsky.social #TTLC25 showing real world outcomes in our cohort treated with tarlatamab at UVA with mentor Rick Hall. Many treated outside DeLLphi-301 eligibility criteria, but ORR still 45%. CRS 73%, ICANS 41%.

23.02.2025 12:53 — 👍 5    🔁 0    💬 1    📌 0

We have known for decade+ that you can detect progression using ctDNA months before you see it on scans. But until we show that it impacts outcomes to change tx earlier all it does is make ppl anxious and abandon treatments (TKIs) that may still be helping. Most MRD use today is marketing over data.

08.12.2024 13:06 — 👍 35    🔁 14    💬 4    📌 1

Graphic showing an increase in 5-year lung cancer survival rates by 22% from 2015 to 2019. Features silhouette figures representing people, with Lung Cancer Research Foundation logo and website LCRF.org/LCAM.

#LungCancer survival rates rose 22% from 2015 to 2019. While promising, we want to see those numbers go much higher…while we're at it, let's shoot for 10, 15, 20 or more years. Learn how you can make an impact this Lung Cancer Awareness Month: buff.ly/4eDVXTo. #LCAM2024

21.11.2024 19:53 — 👍 22    🔁 4    💬 1    📌 1

Graphic comparing women's lives lost to lung, cervical, ovarian, and breast cancers. Nearly 60 thousand die of lung cancer per year, compared with 4,360 cervical, 12,740 ovarian, and 42,250 breast cancer.

More women are lost to #LungCancer than to breast, cervical, and ovarian cancer combined. If you have lungs, you can get lung cancer. Learn more about how this disease affects women: LCRF.org/women. #LCAM2024 @WomenLC

26.11.2024 15:00 — 👍 15    🔁 4    💬 0    📌 1

Genentech: Press Releases | Monday, Nov 25, 2024 Discover the latest news about our company, our products, our policies, and our people.

Press release: phase III SKYSCRAPER-01 study negative for OS at final analysis. Adding anti-TIGIT tiragolumab to first line atezolizumab in advanced PDL1 high NSCLC did not improve PFS or OS. Now to dissect what happened between phase II and III.

www.gene.com/media/press-...

26.11.2024 11:52 — 👍 33    🔁 6    💬 2    📌 3

State of Lung Cancer Examining lung cancer incidence, survival, stage at diagnosis, surgical treatment, lack of treatment, and screening, this report finds states must do more to protect their residents from lung cancer.

National rate is 16%. Varies by state and regions within states. State by state data here:

www.lung.org/research/sta...

26.11.2024 11:12 — 👍 6    🔁 1    💬 1    📌 1

UVA Cancer Center Partnering to Expand Lung Cancer Screenings in Rural Virginia, West Virginia UVA Cancer Center, Appalachian Community Cancer Alliance and Buchanan General Hospital (BGH) have teamed up to make lung cancer screenings easier.

Delighted to see this effort to increase lung cancer screening in areas where it is most needed. Only 7% of eligible individuals get screening for lung cancer. Let’s all aim to improve screening efforts this Lung Cancer Awareness Month! #LCAM, #lcsm, #OncSky

bit.ly/3AMDSot

26.11.2024 00:48 — 👍 14    🔁 1    💬 1    📌 0

Just gave my 1st line lecture last week. I also briefly cover ECOG 1594, Scagliotti et al. Cis/Pem vs. Cis/Gem, and PARAMOUNT, so they understand the data supporting the chemo backbone of current regimens and show them how far we've come. But I keep cutting these slides back each year to make room!

25.11.2024 03:04 — 👍 4    🔁 0    💬 0    📌 0

Trying to get up to speed on #BlueSky. Great list to get started! Thanks, @n8pennell.bsky.social

#OncSky #LCSM

24.11.2024 14:51 — 👍 2    🔁 0    💬 0    📌 0